ReviewPharmaceutics2026
Novel AI-Driven Precision Strategies in Diabetic Wound Healing: Immunomodulation and Advances in Smart Composite Nanocarriers.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Confidence-Gated Triage: Coupling Drug-Target Affinity and ADME-T Predictions to Prioritise Compounds for Docking.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Neuroimmune Regulation in Posttraumatic Bone Repair: From Inflammatory Transition to Neurovascular Coupling and Functional Recovery.Journal of cellular physiology · 2026Review
- Hyaluronic Acid-Based Biomaterials for Soft Tissue Repair and Wound Healing: Clinical Evidence and Emerging Applications.Gels (Basel, Switzerland) · 2026Review
- Multifunctional Hydrogels for Diabetic Wound Healing: Design Strategies and Microenvironmental Remodeling Mechanisms.Gels (Basel, Switzerland) · 2026Review
- [Role and mechanism of Wnt9a in human and mouse chronic wound healing].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Diabetic chronic wounds (CWs) represent a recalcitrant, difficult-to-heal pathological condition characterized by an imbalance of the immune microenvironment. Smart composite nanocarriers for immune regulation enable multi-targeted, spatiotemporally controllable synergistic interventions by responding to pathological signals such as reactive oxygen species (ROS), pH, and abnormal enzyme activity, thereby offering a novel pharmaceutical strategy to overcome the limitations of traditional single-target therapies. Artificial intelligence (AI) integrates clinical and biological data to predict healing risks, optimize treatment plans and nanocarrier design, and dynamically adjust strategies based on patient conditions, ensuring precision and personalized therapies. This paper systematically reviews the immunopathological basis of CWs, summarizes the design rationale and functional evolution of immune-modulating smart composite nanocarriers, and discusses an AI-enabled precision therapy framework from an interdisciplinary perspective. It aims to establish a theoretical foundation and research paradigm for constructing programmable drug delivery systems tailored to complex disease microenvironments, facilitating the transition of smart nanopharmacy from material-oriented to system-regulation-oriented approaches, and accelerating the clinically predictable translation of diabetic wound therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.